| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/23/2010 | US7666849 Ribosome structure and protein synthesis inhibitors |
| 02/23/2010 | US7666844 Dry mouldable drug formulation |
| 02/23/2010 | US7666843 Methods and compositions for treatment of neurological disorder |
| 02/23/2010 | US7666842 Elastin peptide analogs and uses thereof |
| 02/23/2010 | US7666841 for the treatment of diseases and pathological alterations associated with excessive or deregulated TGF- beta 1 expression |
| 02/23/2010 | US7666840 α-Conotoxin peptides |
| 02/23/2010 | US7666839 Methods of treatment using specific binding agents of human angiopoietin-2 |
| 02/23/2010 | US7666838 Analogs of gastric inhibitory polypeptide and their use for treatment of diabetes |
| 02/23/2010 | US7666837 Methods and compositions for producing secreted trimeric receptor analogs and biologically active fusion proteins |
| 02/23/2010 | US7666836 administering a luteinizing hormone releasing hormone antagonist selected from cetrorelix, teverelix, ganirelix, antide, abarelix etc. in the form of a short term induction treatment for a period of about 4 to 12 weeks to a patient for treating eddometriosis |
| 02/23/2010 | US7666835 oxyntomodulin a polypeptide is administered to a obese mammal by oral, parenteral, mucosal, rectal subcutaneous or transdermal administration |
| 02/23/2010 | US7666834 (2-Pyrazol-1-yl-5-trifluoromethylphenyl)carbamic acid 4-cyclopropanesulfonylamino-carbonyl-13-methyl-2,14-dioxo-3,13-diazatricyclo-[13.3.0.04,6]octadec-7-en-17-yl ester; viricides; potency, decreased cytotoxicity, improved pharmacokinetics, improved resistance profile; liver disorders; ritonavir |
| 02/23/2010 | US7666833 Using hormone treatments to prevent and/or treat glucose metabolism disorers |
| 02/23/2010 | US7666832 Administering peptibodies, i.e., peptides fused to other molecules such as an Fc domain of an antibody, where the peptide moiety specifically binds to Ang-2 ( angiopoietin-2); antiinflammatory agent; antirheumatic agent |
| 02/23/2010 | US7666831 Administering peptibodies, i.e., peptides fused to other molecules such as an Fc domain of an antibody, where the peptide moiety specifically binds to Ang-2 ( angiopoietin-2); antiinflammatory agent; antirheumatic agent |
| 02/23/2010 | US7666830 Nutritional composition preventing bacterial overgrowth |
| 02/23/2010 | US7666829 Compositions for elastogenesis and connective tissue treatment |
| 02/23/2010 | US7666651 Polypeptide having heparanase activity |
| 02/23/2010 | US7666647 Unphosphorylated glycogen synthase kinase-3-g-beta (GSK) from baculovirus overexpression system; competitive binding; diabetes, Alzheimer's disease |
| 02/23/2010 | US7666639 Plant deoxyribonucleoside kinase enzymes and their use |
| 02/23/2010 | US7666626 P4 variant protein that has reduced enzymatic activity and that induces antibody to wild-type P4 protein and/or has good bactericidal activity against non-typable H. influenzae (NTHi) |
| 02/23/2010 | US7666624 Chemically conjugating a peptide of interest to a heterologous peptide that has been expressed on the coat protein of a cowpea mosaic virus to generate a conjugate and administering the conjugate to a host animal to increase the level of TH1-type immune response |
| 02/23/2010 | US7666621 Has an apparent molecular weight of 42,000 Daltons; fusion protein of the protein D bound to a polypeptide, carbohydrate, or matrix; prepared by providing a non-human host containing a plasmid or phage comprising a DNA nucleotide sequence and expressing the encoded protein D |
| 02/23/2010 | US7666619 Compounds and methods for regulating bacterial growth and pathogenesis |
| 02/23/2010 | US7666613 psychiatric disorders; serine protease; genetic engineering; schizophrenia |
| 02/23/2010 | US7666610 Expressing transporters on viral envelopes |
| 02/23/2010 | US7666604 Modified soluble T cell receptor |
| 02/23/2010 | US7666582 Immunoglobulin G-degrading enzyme for use as tool in diagnosis, prevention and treatment of streptococcal infection |
| 02/23/2010 | US7666581 Complexing antigenic proteins/peptides; membrane proteins; tumor associated antigens |
| 02/23/2010 | US7666441 Nucleic acids encoding peptides having at least one biological activity of Can f I or Can f II, protein allergens of the species Canis familiaris; suitable for pharmaceutical administration or methods of diagnosing sensitivity to dog dander |
| 02/23/2010 | US7666437 Containing a terminal cysteine, wherein when administered by intranasal route to mammals, it generates an immune response in Peyer patches, inguinal, cervical lymphatic ganglions and in the spleen that confers protection from illness caused by enterotoxigenic Escherichia Coli |
| 02/23/2010 | US7666435 Treatment of fine wrinkles with clostridia neurotoxins |
| 02/23/2010 | US7666434 Screening blood and identifying immunologically active antigen of herpes simplex virus (HSV) which attacks skin; diagnosing viral infection; viricides |
| 02/23/2010 | US7666432 Suppressing fibrosis in a mammal having a fibrosing disease by administering a Serum Amyloid P (SAP) protein; treatment of diseases such as scleroderma, pulmonary fibrosis and asthma |
| 02/23/2010 | US7666430 Polypeptides and polynucleotides for enhancing immune reactivity to HER-2 protein |
| 02/23/2010 | US7666429 Nucleic acids encoding a house dust mite allergen Der P III, and uses therefor |
| 02/23/2010 | US7666428 Recombinant allergen with reduced IgE binding but undiminished T-cell antigenicity |
| 02/23/2010 | US7666425 Use of antibodies or binding portions thereof, probes, ligands, or other biological agents which either recognize an extracellular domain of prostate specific membrane antigen or bind to and are internalized with prostate specific membrane antigen |
| 02/23/2010 | US7666422 Methods for the treatment of cancer using anti-CD40 antibodies |
| 02/23/2010 | US7666416 Mammalian cell culture process |
| 02/23/2010 | US7666413 For subcutaneous administration; hypertonic; useful for preventing self-association of reconstituted lyophilized formulations |
| 02/23/2010 | US7666412 Methods for the treatment of neoplastic disorders with anti-caveolin agents |
| 02/23/2010 | US7666408 Virus-like particle of an RNA bacteriophage carrier attached to an angiotensin peptide through a nonpeptide bond to form an ordered and repetitive angiotensin peptide-carrier conjugate; treating/preventing hypertension, stroke, infarction, congestive heart failure, kidney failure and retinal hemorrhage |
| 02/23/2010 | US7666405 Deleted adenovirus vectors and methods of making and administering the same |
| 02/23/2010 | US7666403 Mutant interferon α protein and use thereof |
| 02/23/2010 | US7666402 Use of IL-22 for the treatment of conditions of metabolic disorders |
| 02/23/2010 | US7666401 Compositions comprising a ligand of Chemerin R |
| 02/23/2010 | US7666400 PEGylation by the dock and lock (DNL) technique |
| 02/23/2010 | US7666391 Therapeutic treating breast cancer |
| 02/23/2010 | CA2498934C Compositions for inducing increased levels of .beta.-chemokines and methods of use therefor |
| 02/23/2010 | CA2448596C Topical treatments using alkanolamines |
| 02/23/2010 | CA2428641C Functional fragment of the leptin receptor |
| 02/23/2010 | CA2400826C Methods and compositions for treating intervertebral disc degeneration |
| 02/23/2010 | CA2378945C Multi-dose erythropoietin formulations |
| 02/23/2010 | CA2378880C Solutions and methods for inhibition of pain, inflammation and cartilage degradation |
| 02/23/2010 | CA2355834C Human akt-3 |
| 02/23/2010 | CA2315277C Pharmaceutical compositions containing the long pentraxin ptx3 |
| 02/23/2010 | CA2289499C Somatostatin and somatostatin agonists for treating insulin insensitivity and syndrome x |
| 02/23/2010 | CA2257852C Transgenic non-human mammals with progressive neurologic disease |
| 02/23/2010 | CA2232288C Treating niddm with rxr agonists |
| 02/23/2010 | CA2198899C Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| 02/23/2010 | CA2138999C Cloning and expression of gonadotropin-releasing hormone receptor |
| 02/23/2010 | CA2138933C Use of bradykinin antagonists for the preparation of medicaments for the treatment of virus diseases |
| 02/18/2010 | WO2010019965A1 Compositions and methods for modulating epsilon protein kinase c-mediated cytoprotection |
| 02/18/2010 | WO2010019954A2 Purine nucleoside phosphorylase as enzymatic activator of nucleoside prodrugs |
| 02/18/2010 | WO2010019847A2 Aptamer inhibition of thrombus formation |
| 02/18/2010 | WO2010019839A1 Methods for using interferon gamma to absorb fluid from the subretinal space |
| 02/18/2010 | WO2010019717A2 Combination therapy of hiv fusion/entry inhibitors targeting gp41 |
| 02/18/2010 | WO2010019698A2 Inhibition of calicivirus (norovirus) |
| 02/18/2010 | WO2010019694A1 Micro-rna-based compositions and methods for the diagnosis, prognosis and treatment of multiple myeloma |
| 02/18/2010 | WO2010019276A2 Method and formulation for treating adverse biological conditions |
| 02/18/2010 | WO2010019275A2 Compositions and methods for treatment during non-acute periods following cns neurological injury |
| 02/18/2010 | WO2010019266A2 Stable solid formulation of a gc-c receptor agonist polypeptide suitable for oral administration |
| 02/18/2010 | WO2010019263A2 Soluble flt constructs for treating cancers |
| 02/18/2010 | WO2010019261A1 Use of gdf traps to increase red blood cell levels |
| 02/18/2010 | WO2010019257A2 Prodrug activation in cancer cells using molecular switches |
| 02/18/2010 | WO2010019120A1 S0x9, prostaglandin d2 and retinoic acid for treating pigmentary conditions and melanoma |
| 02/18/2010 | WO2010019103A1 The use of wnt5-a peptide derivates for the treatment of melanoma and gastric cancer |
| 02/18/2010 | WO2010018918A1 Agent comprising g-csf for treatment or prevention of neuropathic pain and method for treating neuropathic pain with the same |
| 02/18/2010 | WO2010018847A1 Recombinant protein-s composition |
| 02/18/2010 | WO2010018731A2 A mammalian rna dependent rna polymerase |
| 02/18/2010 | WO2010018652A1 Agent for promoting neuronal differentiation and method therefor |
| 02/18/2010 | WO2010018167A1 Dental formulations for the prevention of dental erosion |
| 02/18/2010 | WO2010018159A1 Pharmaceutical compositions |
| 02/18/2010 | WO2010017965A2 SOLID LIPID MICROCAPSULES CONTAINING hGH |
| 02/18/2010 | WO2010017912A2 Use of human hyaluronidases for axonal regrowth |
| 02/18/2010 | WO2010017743A1 The injectable sustained-release formulation of lhrh antagonists and the preparation thereof |
| 02/18/2010 | WO2010017653A1 Gq protein competitive inhibitory polypeptides, preparation methods and uses thereof |
| 02/18/2010 | WO2010017632A1 Methods for stimulating chondrogenesis utilizing a potassium channel inhibitor |
| 02/18/2010 | WO2010017587A1 Novel protease inhibitors |
| 02/18/2010 | WO2009155258A3 Glucagon/glp-1 receptor co-agonists |
| 02/18/2010 | WO2009150252A3 Process for the preparation of depeptides from cyanophycin employing the isolated pseudomonas alcaligenes dip1 cgpase cpheal |
| 02/18/2010 | WO2009137829A9 Directed stem cell recruitment |
| 02/18/2010 | WO2009126898A3 Humanized monoclonal antibodies that specifically bind and/or neutralize japanese encephalitis virus( (jev) and their use |
| 02/18/2010 | WO2009120893A3 Polypeptide-polymer conjugates and methods of use thereof |
| 02/18/2010 | WO2009117616A3 Carbon nanotube compositions and methods of use thereof |
| 02/18/2010 | WO2009114826A3 Treatment systems and methods for renal-related diseases |
| 02/18/2010 | WO2009114679A3 Treatment of pompe disease with specific pharmacological chaperones and monitoring treatment using surrogate markers |
| 02/18/2010 | WO2009083203A3 Topical application and formulation of erythropoietin for skin wound healing |
| 02/18/2010 | WO2009080778A4 Preparations with rosehip extracts, and method of producing rosehip extracts |